Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate

Antimicrob Agents Chemother. 2005 Oct;49(10):4386-9. doi: 10.1128/AAC.49.10.4386-4389.2005.

Abstract

A study explored the pharmacokinetics of tenofovir (300 mg administered once daily) and nelfinavir (1,250 mg twice daily) when coadministered in 29 healthy volunteers. Tenofovir, nelfinavir, and M8 pharmacokinetics was unaltered when tenofovir and nelfinavir were coadministered, and tenofovir administration did not affect the M8/nelfinavir area under the concentration-versus-time curve over the dosing interval (AUC(tau)) ratio. No interaction between tenofovir and nelfinavir was observed.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Adenine / blood
  • Adenine / pharmacokinetics
  • Adenine / therapeutic use
  • Adult
  • Area Under Curve
  • Drug Therapy, Combination
  • Female
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / blood
  • HIV Protease Inhibitors / pharmacology*
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Male
  • Nelfinavir / administration & dosage
  • Nelfinavir / blood
  • Nelfinavir / metabolism
  • Nelfinavir / pharmacokinetics*
  • Nelfinavir / therapeutic use
  • Organophosphonates / administration & dosage
  • Organophosphonates / blood
  • Organophosphonates / pharmacokinetics*
  • Organophosphonates / therapeutic use
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / blood
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Tenofovir

Substances

  • HIV Protease Inhibitors
  • Organophosphonates
  • Reverse Transcriptase Inhibitors
  • Tenofovir
  • Nelfinavir
  • Adenine